Navigation Links
ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
Date:6/16/2008

SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today provided an update with regard to overall survival from its Phase 2b clinical trial of CoFactor for the treatment of first-line metastatic colorectal cancer. Overall survival results in this study have been revised upwards slightly, with the CoFactor/5-FU (5-fluorouracil) arm demonstrating a 14 day improvement in overall survival compared to the leucovorin/5-FU arm.

"In the Phase 2b study, CoFactor was dosed at 60mg/m2 by infusion to provide as unbiased a comparison as possible to leucovorin, which is administered at 200 mg/m2 by infusion over about 2 hours in this setting," stated Evan M. Levine, Chief Executive Officer and President of ADVENTRX. "Even while administering CoFactor over hours instead of the more optimal 2 to 3 minute bolus administration, and at a significantly lower dose of the folate, we were able to demonstrate a numerical advantage with respect to overall survival and progression-free survival with CoFactor plus 5-FU in this study, which is encouraging."

Consistent with its previous guidance, the Company anticipates announcing available interim data from its discontinued Phase 3 trial of CoFactor for the treatment of first line metastatic colorectal cancer later this month. Furthermore, the Company is on track to announce its decision about how to best move forward with its CoFactor program later this month.

About the CoFactor Phase 2b Study

The Phase 2b clinical trial was an international, open-label, randomized, controlled, multicenter study designed to evaluate the safety and efficacy of treatment with CoFactor/5-FU compared to leucovorin/5-FU utilizing an infusional administration in patients wi
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
2. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
3. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
4. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
5. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
6. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
7. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. Disc Motion Technologies Announces First Human Implants of True TSMS(TM) Device
10. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
11. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...PRNewswire-FirstCall/--Hologic,Inc.(HologicortheCo...erandsupplierofpremiumdiagnostics,medicalimagingsy...hcareneedsofwomen,isusingtheannualmeetingoftheRadi...einChicago,November29throughDecember3,2009tohighli...cmammographyworkstationsoftware. ,, TheHologicS...
(Date:11/25/2009)...RNewswire-FirstCall/--ERT(Nasdaq: ERES ),announced...tandCEO,andKeithSchneck,theCompany,sExecutiveViceP...lPiperJaffrayHealthCareConferenceat1:30PMESTonDece...artiesmayaccessthepresentationbyvisitingtheCompany...tmayalsobeaccessedat http://www.corporate-ir.net/i...
(Date:11/25/2009)...wswire/--BioTrendsResearchGroup,Inc.releasedWave1o...tinamulti-phasesyndicatedmarketresearchprojecttrac...productlaunchthroughthefirstsixmonthsofavailabilit...onfrom75uniqueDermatologistsandqualitativeinformat...elara,obstaclestouse,typicalpatienttypes,productpe...
Breaking Medicine Technology:New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2New 21 The Groove Optic 28TM 29 for the Lux2940 28TM 29 3A A Breakthrough in Fractional Skin Resurfacing 6357 1New 21 The Groove Optic 28TM 29 for the Lux2940 28TM 29 3A A Breakthrough in Fractional Skin Resurfacing 6357 2New 21 The Groove Optic 28TM 29 for the Lux2940 28TM 29 3A A Breakthrough in Fractional Skin Resurfacing 6357 3News brief 3A Adverse symptom reporting by patients vs clinicians 61572 1News brief 3A Adverse symptom reporting by patients vs clinicians 61572 2When East meets West 3A Why consumers turn to alternative medicine 61567 1When East meets West 3A Why consumers turn to alternative medicine 61567 2
...April 18, 2007--Due to water damage caused by,floo...ge the,location for the upcoming Antiviral Drugs A...cuss new drug application for,maraviroc 300 millig...e FDA, Center for Drug Evaluation and Research Adv...s Lane, in Rockville, MD, the,meeting has been rel...
... pain progression is 66.1 weeks for the,satraplati... --,Hazard ratio of 0.64 (95% CI: 0.51-0.79, p<0.0...risk of pain progression, MARTINSRIED/MUNICH, Germ...TON, N.J., and BOULDER, Colo. -- GPC Biotech AG an...ation of additional,data from the double-blind, ra...
Other Medicine Technology:FDA Announces Change of Location Notice for Upcoming Advisory,Committee Meeting 2Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 2Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 3Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 4Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 5Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 6
(Date:11/26/2009)...No more letters from the North Pole, Textsanta.net...es from Santa , North Pol...nal efficiencies at the North Pole Santa Claus has...l over the globe informed of his Christmas progres...search department have identified a large and grow...
(Date:11/26/2009)...Ennis & Ennis, P.A. is offering free nationwid...Yasmin birth control pills who have suffered a Dee...e, Heart Attack or other related cardiac issues or...l free at 1-800-856-6405 or go to the firm’s... an online case evaluation form. , ...
(Date:11/25/2009)...Nov.25/PRNewswire/-SentinelleMedicalInc.,aleadingm...softwareandCalgaryScientificInc.,aleadingprovidero...rsionofAegis(TM)Breast4DAdvancedVisualizationsoftw...ero-footprintWebclientbasedmedicalimagingofferingi...llowsforzero-footprintaccess-requiringnosoftwaredo...
(Date:11/25/2009)...PRNewswire-USNewswire/--TheBlackAIDSInstituterecen...eleadershipfor2010. ,, ThenewBoardMembersareahi...licy,law,finance,governmenthealthprograms,editoria...mawiderangeofpersonalbackgroundsincludingbothheter...mselves,andrepresentingmultipleagegroups. ,, (P...
(Date:11/25/2009)...vidence of a statistically significant survival be... estrogen receptor (ER)-positive tumors had high l...8 (ER-alpha S118-P), according to a brief communic... of the National Cancer Institute . , Approximat...xifen. Preclinical studies have shown that ER-alph...
Breaking Medicine News(10 mins):Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:Black AIDS Institute Announces 2010 Board Election Results 2
... know that, diseases are a result of paucity of mi...ction of minerals is to maintain the alkaline body...th should be slightly alkaline and within the rang... to feel down in the dumps. Therefore it is impera...
...Indian Feasts', the latest cookbook by Britain-bas...ourmand World Cookbook Award' in the 'Best Asian C...ns the popular Spice Route restaurant in Windsor, ...lutely overwhelmed and highly honoured by this awa...
...been a question of eternal debate and research as ...r and the limited selection of healthy foods in th... author Sanae Inagami, M.D., a researcher with the...ami’s words, 'My feeling is that your neighbors do...
... you thought that you were a great exercise buff a...rces of urban air pollution, you might have to do ...cording to an environmentalist exhaust and smoke f...nical Medicine and Patient Safety Officer at NewYo...
...hers can now perform gene mapping, ten times faste...time of linked computers// and unwind the mysterie...f the study, conducted by researchers from Technio...ystem reduces the time-consuming process of identi...
...ng to a funded study by EU, Europeans are the heav...ohol-related deaths reported costing about billion... Alcohol is responsible for 7.4 percent of all il...ure. Drinking causes some 60 different types...
Other Medicine News:Health News:Sleeping Computers Yield Clues About Genetic Disorders 2Health News:Europeans Tops the World in Alcohol Consumption 2
...mb motion can be difficult for persons who have su...ries and for children with poor hand control due t...oblems. The FoamWrap ThumDuction Strap positions t...ined material provides light control and positioni...
...ed FoamWrap ThumWrap Splints offer support without...to relieve mild pain or strain due to repetitive s...r the rigid or the flexible stay to provide just t...e, the ThumWrap Splint is comfortable to wear even...
...OTS is an off-the-shelf wrist orthotic designed to...t ranges-of-motion (20°,35° and 50°). ... sprains with TFCC tear-triangular fibrocartilage ...phoid nonunion , Partial tendon rupture , ORIF...
Wrist Hand Orthosis
Medicine Products: